The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of intravenous PI3K inhibitor BAY 80-6946: Activity in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma treated in MTD expansion cohorts.
Michael T. Lotze
No relevant relationships to disclose
Leonard Joseph Appleman
Research Funding - Bayer
Ramesh K. Ramanathan
Research Funding - Bayer
Anthony W. Tolcher
Consultant or Advisory Role - Bayer
Research Funding - Bayer
Muralidhar Beeram
No relevant relationships to disclose
Kyriakos P. Papadopoulos
Research Funding - Bayer
Drew Warren Rasco
Research Funding - Bayer
Glen J. Weiss
Consultant or Advisory Role - Bayer
Research Funding - Bayer
James M Mountz
No relevant relationships to disclose
Frederico G.S. Toledo
No relevant relationships to disclose
Rene J Alvarez
No relevant relationships to disclose
Matthew J Oborski
No relevant relationships to disclose
Prabhu Rajagopalan
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Michael Jeffers
Employment or Leadership Position - Bayer
Diane Roth
Employment or Leadership Position - Bayer (I)
Ronald L. Dubowy
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Amita Patnaik
Research Funding - Bayer